Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nichi-Iko Offers Heartfelt Apology As It Forecasts Huge Annual Loss

As Analyst Warns: Pharmacies And Medical Institutions ‘May Start To Desert Nichi-Iko’

Executive Summary

Nichi-Iko’s first-half financial results made for unhappy reading again as the company’s bottom line was battered by longstanding quality problems, leading the firm to announce huge projected losses for its current financial year ending in March 2022.

You may also be interested in...



Keppra And Velcade Rivals Among Sawai’s New Listings

Rivals to Careram, Keppra, Patanol, Velcade and Volibris have been listed with Japan’s NHI drug price list by Sawai, as the company seeks to capitalize on its position as a leading supplier in the market.

Sawai To Take Over Facilities Owned By Scandal-Hit Kobayashi Kako

Kobayashi Kako has agreed to transfer ownership of eight of its production, research and distribution facilities to Sawai, which will use them to expand the manufacturing of its own generics. Business was suspended at Kobayashi Kako for 116 days this year after the company’s manufacturing deficiencies were linked to two deaths.

Towa Raises Japanese Expectations Amid Uncertain Business Climate

Towa has issued a minor upward revision to its full-year guidance after its domestic business delivered higher than expected sales and profit growth during H1, but uncertainty in the Japanese generics market and concerns over the firm’s overseas units have led some analysts to raise questions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151442

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel